ArticleInternational journal of clinical and experimental pathology2018
Serum miR-10a-5p and miR-196a-5p as non-invasive biomarkers in non-small cell lung cancer.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- High diagnostic value of miRNAs for NSCLC: quantitative analysis for both single and combined miRNAs in lung cancer.Annals of medicine · 2021Pooled it
- LncRNA MIR22HG and miR-10a-5p: Pioneering serum biomarkers for pancreatic cancer diagnosis and progression assessment.Non-coding RNA research · 2026Article
- Article
- An RNase domain-dependent microRNA detection with DNA-spiked nanocage for accurate cancer diagnosis.Nature communications · 2026Article
- Urinary biomarkers for lung cancer detection.The journal of liquid biopsy · 2026Article
- MicroRNA-regulated signaling and tumor microenvironment modulation in lung cancer: mechanistic insights and translational opportunities.Cancer cell international · 2026Review
- Translational MicroRNA research in COVID-19: bridging in Silico prediction with clinical biomarker potential.Clinical and experimental medicine · 2026Article
- Divergent Tissue and Circulatory Expression of miR-10a in Canine Hepatocellular Carcinoma: Comparative Insights from Human HCC.Current issues in molecular biology · 2025Article
- Integration of Circulating miR-31-3p and miR-196a-5p as Liquid Biopsy Markers in HPV-Negative Primary Laryngeal Squamous Cell Carcinoma.Diseases (Basel, Switzerland) · 2025Article
- Potential diagnostic and prognostic biomarkers of pediatric Burkitt lymphoma identified through miRNA expression profiling.Pediatric research · 2025Article
- Identifying Common Diagnostic Biomarkers and Therapeutic Targets between COPD and Sepsis: A Bioinformatics and Machine Learning Approach.International journal of chronic obstructive pulmonary disease · 2025Article
- Serum extracellular vesicle microRNAs as potential biomarkers to predict pembrolizumab response and prognosis in metastatic non-small cell lung cancer patients.Frontiers in immunology · 2025Article
- Modulation of the cytoskeleton for cancer therapy.Frontiers in cell and developmental biology · 2025Article
- Genetic variants in mitochondrial sirtuins associated with brain tumor risk: a case-control study.Future oncology (London, England) · 2024Article
- The Regulation of Fatty Acid Synthase by Exosomal miR-143-5p and miR-342-5p in Idiopathic Pulmonary Fibrosis.American journal of respiratory cell and molecular biology · 2024Article
- Transcriptome Analysis and Epigenetics Regulation in the Hippocampus and the Prefrontal Cortex of VPA-Induced Rat Model.Molecular neurobiology · 2024Article
- miR-124 as a Liquid Biopsy Prognostic Biomarker in Small Extracellular Vesicles from NSCLC Patients.International journal of molecular sciences · 2023Article
- Potential Role of miR-196a and miR-196b as Prognostic Biomarkers of Survival in Head and Neck Squamous Cell Carcinoma: A Systematic Review, Meta-Analysis and Trial Sequential Analysis.Life (Basel, Switzerland) · 2022Review
- Article
- The diagnostic and prognostic values of microRNA-196a in cancer.Bioscience reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all cases. MicroRNAs are stable molecules in the blood and can be used as biomarkers for early diagnosis of various malignancies. The aim of this study was to evaluate expression of miR-10a-5p and miR-196a-5p in tissue and serum of patients with NSCLC and to explore its relationship with clinicopathological characteristics.
methodsA total of 20 pairs of tissues and 80 serum samples were obtained from NSCLC patients. Seventy-five serum samples from healthy individuals of the same age and gender were also collected. The expression level of miR-10a-5p and miR-196a-5p was detected by quantitative real-time PCR. The relationship between miR-10a-5p and miR-196a-5p expression level in NSCLC tissues and serum and clinicopathological characteristics was estimated respectively. The diagnostic value of miRNA-10a-5p and miR-196a-5p in NSCLC was assessed by the Receiver-operating characteristic (ROC) curve method.
resultsWe found that miRNA-10a-5p and miR-196a-5p expression levels were increased significantly in NSCLC tissues compared with non-tumor adjacent normal tissues. Serum miR-10a-5p and miR-196-5p were over-expressed in NSCLC patients compared with healthy controls. The higher miR-10a-5p or miR-196-5p expression levels were positively correlated with advanced tumor stage and positive lymph node metastasis. The area under the curve (AUC) of serum miR-10a-5p and miR-196-5p to diagnose NSCLC were 0.709 and 0.785. Optimal sensitivity and specificity were 65.98% and 72.71%, 67.86% and 77.57%, respectively in differentiating NSCLC patients from healthy controls. The combination of these two miRNAs with carcinoembryonic antigen (CEA) further increased the diagnostic value, with an area under the curve (AUC) of 0.801 (sensitivity, 76.34%; specificity, 79.26%) using logistic regression model analysis.
conclusionsSerum miR-10a-5p and miR-196a-5p may be useful noninvasive biomarkers for the clinical diagnosis of NSCLC.
Indexed as
Identifiers
31938164PMC6958018W3027703307What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.